Effects of D-Chiral Inositol on Amino Acid Metabolism in a PCOS Rat Model

Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects fertility through oligo weathering, hyperandrogenism, and polycystic morphology of the ovary. Currently, D-chiral inositol (DCI) treatment of PCOS has yielded satisfactory results by targeting steroid biosynthesis, but a deeper understanding of the potential mechanisms and efficacy of this treatment regimen is needed. The aim of this study was to determine the effects of DCI use on endocrine and metabolic abnormalities in women with PCOS.

A PCOS rat model was developed via letrozole induction. After successful modeling, letrozole was administered orally to the rats for 4 weeks (PCOS + DCI). Enzyme-linked immunosorbent assay was used to examine changes in serum hormone levels in PCOS rats and PCOS + DCI rats, and transcriptomics was used to detect changes in the expression of related target genes and signaling pathways. Furthermore, amino acid-targeted metabolomics was performed.

DCI intervention effectively improved the symptoms of PCOS in the rats, including polycystic ovary-like changes and serum sex hormone and insulin levels. Further transcriptomic validation showed significant changes in the expression of genes such as Lamc2, Inhba, and Bdkrb2 in DCI-treated rats. Metabolomic validation targeting amino end groups revealed that DCI effectively improved amino acid metabolism in PCOS rats.

This study confirmed that DCI can not only alleviate the reproductive and metabolic abnormalities of PCOS phenotypically but also regulate gene expression and metabolic networks at the molecular level. Its therapeutic effect has the characteristics of being multitarget and systematic.